IL10 and neoplasm: Furthermore, treatment of CLL cells with ibrutinib and venetoclax, after coculturing the tumor cells with TME agonists such as interleukin-10 (IL-10), CD40L, and CpG-ODNs (TLR-9 specific agonists), led to the activation of the NF-κB signaling pathway (especially alternative NF-κB).